Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been implicated in vascular calcification pathogenesis. CKD-MBD results in alterations in the number and function of circulating endothelial progenitor cells (EPCs), physiological regulators of angiogenesis and vessel repair, commonly defined as proangiogenic progenitor cells (PACs) by the antigen pattern CD34+CD133+KDR+CD45- and putative EPCs by the pattern CD34+CD133-KDR+CD45-. These cells might acquire a calcifying phenotype in CKD-MBD, expressing mineralization biomarkers. We investigated the expression of vitamin D receptor (VDR) and osteocalcin (OC) on EPCs of healthy individuals and haemodialysis patients, and their possible associations with circulating biomarkers of inflammation and vascular calcification. Methods: We compared EPC counts, expressing VDR or OC, in 23 healthy subjects versus 53 haemodialysis patients, 17 of them without vitamin D receptor agonist (VDRA) therapy and 35 treated with calcitriol (n = 17) or paricalcitol (n = 18). The correlations with serum levels of inflammatory and calcification indexes were also analysed. Results: All subsets expressing VDR or OC were significantly higher in haemodialysis patients compared with healthy controls, but PACs were increased only in VDRA treatment subgroup, while putative EPCs showed a similar rise also in untreated patients. In VDRA-untreated patients, OC+ PACs correlated positively with calcium levels, while in VDRA-treated patients, VDR+ PACs correlated positively with interleukin 6 levels, and OC+ PACs correlated positively 25-hydroxyvitamin D levels. Conclusions: Our data suggest that in CKD-MBD, EPCs undergo an endothelial-to-procalcific shift, representing a risk factor for vascular calcification. A link between mineral disorders and vitamin D replacement therapy emerged, with potential adverse effects for CKD patients.
Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been implicated in vascular calcification pathogenesis. CKD-MBD results in alterations in the number and function of circulating endothelial progenitor cells (EPCs), physiological regulators of angiogenesis and vessel repair, commonly defined as proangiogenic progenitor cells (PACs) by the antigen pattern CD34+CD133+KDR+CD45- and putative EPCs by the pattern CD34+CD133-KDR+CD45-. These cells might acquire a calcifying phenotype in CKD-MBD, expressing mineralization biomarkers. We investigated the expression of vitamin D receptor (VDR) and osteocalcin (OC) on EPCs of healthy individuals and haemodialysis patients, and their possible associations with circulating biomarkers of inflammation and vascular calcification. Methods: We compared EPC counts, expressing VDR or OC, in 23 healthy subjects versus 53 haemodialysis patients, 17 of them without vitamin D receptor agonist (VDRA) therapy and 35 treated with calcitriol (n = 17) or paricalcitol (n = 18). The correlations with serum levels of inflammatory and calcification indexes were also analysed. Results: All subsets expressing VDR or OC were significantly higher in haemodialysis patients compared with healthy controls, but PACs were increased only in VDRA treatment subgroup, while putative EPCs showed a similar rise also in untreated patients. In VDRA-untreated patients, OC+ PACs correlated positively with calcium levels, while in VDRA-treated patients, VDR+ PACs correlated positively with interleukin 6 levels, and OC+ PACs correlated positively 25-hydroxyvitamin D levels. Conclusions: Our data suggest that in CKD-MBD, EPCs undergo an endothelial-to-procalcific shift, representing a risk factor for vascular calcification. A link between mineral disorders and vitamin D replacement therapy emerged, with potential adverse effects for CKDpatients.
Entities:
Keywords:
haemodialysis; osteocalcin; vascular calcification; vitamin D receptor; vitamin D receptor agonist therapy
Authors: William E Moody; Nicola C Edwards; Melanie Madhani; Colin D Chue; Richard P Steeds; Charles J Ferro; Jonathan N Townend Journal: Atherosclerosis Date: 2012-02-02 Impact factor: 5.162
Authors: Guiti Z Eghbali-Fatourechi; Ulrike I L Mödder; Natthinee Charatcharoenwitthaya; Arunik Sanyal; Anita H Undale; Jackie A Clowes; James E Tarara; Sundeep Khosla Journal: Bone Date: 2007-01-04 Impact factor: 4.398
Authors: Yuen-Fung Yiu; Yap-Hang Chan; Kai-Hang Yiu; Chung-Wah Siu; Sheung-Wai Li; Lai-Yung Wong; Stephen W L Lee; Sidney Tam; Eric W K Wong; Bernard M Y Cheung; Hung-Fat Tse Journal: J Clin Endocrinol Metab Date: 2011-02-16 Impact factor: 5.958
Authors: Joseph A Hyder; Matthew A Allison; Nathan Wong; Agnes Papa; Thomas F Lang; Claude Sirlin; Susan M Gapstur; Pamela Ouyang; J Jeffrey Carr; Michael H Criqui Journal: Am J Epidemiol Date: 2008-12-08 Impact factor: 4.897
Authors: Sophie A Millar; Stephen G John; Christopher W McIntyre; Vera Ralevic; Susan I Anderson; Saoirse E O'Sullivan Journal: Front Endocrinol (Lausanne) Date: 2020-06-10 Impact factor: 5.555
Authors: Alexander W W Langford-Smith; Ahmad Hasan; Ria Weston; Nicola Edwards; Alan M Jones; Andrew J M Boulton; Frank L Bowling; S Tawqeer Rashid; Fiona L Wilkinson; M Yvonne Alexander Journal: Sci Rep Date: 2019-02-19 Impact factor: 4.379
Authors: Zhenqi Rao; Yidan Zheng; Li Xu; Zihao Wang; Ying Zhou; Ming Chen; Nianguo Dong; Zhejun Cai; Fei Li Journal: Front Cardiovasc Med Date: 2022-06-16